03 February 2017
Several Big Pharma chiefs joined Bradway for the session with Trump. And in most cases, they represent global companies that have been bending over backwards to rein in R&D costs and hold the line on spending, particularly in the US. In a couple of cases, you’ll find some heavy job losses globally, with major cuts directed at US workforces.
Path of Uncertainty: Pharm Exec’s 2017 Industry Forecast
02 February 2017
The populist-driven shifts sweeping the US and EU have triggered plenty of questions when trying to assess the outlook for the global life sciences industry. One certainty, however, amid post-Trump victory and pro-Brexit mandates, will be change, as Pharm Exec’s annual industry forecast explores.
Marinus Appoints Michael R. Dougherty to its Board of Directors
01 February 2017
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Michael R. Dougherty to its Board of Directors.
Market Access 2017: A European Perspective
01 February 2017
Pharm Exec speaks to Ramita Tandon, Executive Vice President, ICON Commercialization & Outcomes, about how the UK and European regulators' market access plans for 2017 will affect the industry.
Report: FDA New Drug Approvals Dip in 2016
01 February 2017
FDA approval of new molecular entities (NMEs) took a sharp decline in 2016 according to a new report released in January 2017 from HBM Partners. In 2016 FDA approved 19 new therapeutic drugs compared to 45 in 2015, the report noted. The official number of novel drugs approved by FDA’s Center for Drug Evaluation and Research (CDER) in 2016 was 22, but this number includes two imaging agents and one antidote, which were not included in the HBM report number.
Pfizer CEO says no need to alter its drug pricing practices
01 February 2017
Pfizer Inc (PFE.N) Chief Executive Ian Read said on Tuesday the company would not change its philosophy on pricing of its medicines or when it takes price increases, bucking a recent trend by some rivals of the largest U.S. drugmaker.
Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board
31 January 2017
Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Lisa M. Coussens, Ph.D., to its Scientific Advisory Board.
Ban DTC or fix it? Docs sound off about patient confusion over ads
31 January 2017
The top 10 drug launches of 2017
31 January 2017
After an unusually slow year for new drug approvals—the FDA greenlighted just 22 meds in 2016—it remains to be seen whether drugmakers can do much better in 2017. One thing’s for sure, though: No matter what total the industry tallies up this year, the crop will bring some would-be blockbusters and market disrupters.
M&A is off to a hot start in 2017; Too bad we can’t say the same for gender parity
30 January 2017
Two big M&A deals Thursday, the $30 billion acquisition of Actelion and Celgene’s pact to acquire newborn Delinia for $300 million upfront, are raising hopes that 2017 will be rich in buyouts.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024
CRISPR technologies fuelling haematological innovations
17 April 2024
17 April 2024